Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179705 | 0.87 | CA2 (0.69) | CA2PSIP1GAASMN1; SMN2FFAR4 | |
| SCHEMBL27277644 | 0.85 | CA2 (0.60) | CA2PSIP1GAASMN1; SMN2FFAR4 | |
| SCHEMBL31681387 | 0.84 | FFAR4 (0.62) | CA2FFAR4ALDH1A1MEN1LMNA | |
| SCHEMBL11889489 | 0.84 | CA2 (0.69) | CA2PSIP1GAASMN1; SMN2FFAR4 | |
| SCHEMBL10767902 | 0.83 | PSIP1 (0.70) | CA2PSIP1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL28163819 | 0.83 | CA2 (0.62) | CA2PSIP1GAASMN1; SMN2RORC | |
| SCHEMBL10455034 | 0.83 | PSIP1 (0.74) | CA2PSIP1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL330903 | 0.82 | CA2 (0.67) | CA2PSIP1SMN1; SMN2FFAR4ALDH1A1 | |
| SCHEMBL6793165 | 0.82 | CA2 (0.67) | CA2SMN1; SMN2FFAR4ALDH1A1MEN1 | |
| SCHEMBL9908320 | 0.81 | PSIP1 (0.68) | CA2PSIP1GAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3207043-B3 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190106460-A1 | BINDING INHIBITORS OF THE BETA. TRANSDUCIN REPEAT-CONTAINING PROTEIN | BRADLEY MARK (GB) | 2019-04-11 | — | — | US | disclosed |
| US-20130244122-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | ONUKI MASAMICHI (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120219866-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2475041-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME | Mitsubishi Chemical Corporation (JP) | 2012-07-11 | — | — | EP | disclosed |
| CN-101420950-B | Treatment of duchenne muscular dystrophy | SUMMIT CORP PLC | 2012-04-18 | — | — | CN | disclosed |
| CN-101420950-A | Treatment of Duchenne muscular dystrophy | SUMMIT CORP PLC (GB) | 2009-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106460-A1 | BINDING INHIBITORS OF THE BETA. TRANSDUCIN REPEAT-CONTAINING PROTEIN | TARDBP, DDB1, EPS15 | CA2 4702/4885PSIP1 3511/4885GAA 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.